RT Journal Article
SR Electronic
T1 An epidemiological and intervention assessment of the malaria epidemic in Bolívar, Venezuela: a modelling study
JF medRxiv
FD Cold Spring Harbor Laboratory Press
SP 2022.04.19.22274042
DO 10.1101/2022.04.19.22274042
A1 John H. Huber
A1 Luis F. Chaves
A1 Amir S. Siraj
A1 Jorge E. Moreno
A1 Maria Eugenia Guevara
A1 Maria Villegas
A1 Leonor Pocaterra
A1 Leopoldo Villegas
A1 T. Alex Perkins
YR 2022
UL http://medrxiv.org/content/early/2022/05/12/2022.04.19.22274042.abstract
AB Background Venezuela has experienced an explosive resurgence in Plasmodium falciparum and Plasmodium vivax malaria incidence over the last decade due to various social, political, and economic factors. To ensure national and regional progress towards malaria elimination, there is an urgent need to better understand the epidemiological dynamics of this malaria outbreak at its epicenter in the southern state of Bolívar and to identify the sets of interventions that may be necessary to reduce transmission and incidence.Methods We fitted transmission models of P. falciparum and P. vivax to weekly incidence data in Bolívar, Venezuela during 2000-2018. We estimated the magnitude of local transmission for both Plasmodium spp. and inferred the contribution of relapses and reinfections to P. vivax incidence in the region. Compared to a business-as-usual scenario, we projected the impact of different interventions on Plasmodium spp. incidence during the period 2021-2023.Findings We estimated that 63·7 – 73·3% of all P. vivax infections in Bolívar are relapses, leading to as many as 51,800 observed relapses misclassified per year as reinfections in the routine surveillance data. Our estimates suggest that the reproduction number remains close to one for both Plasmodium spp., pointing towards the feasibility of control. Long-lasting insecticidal nets (LLINs) were projected to cause greater proportional reductions in P. falciparum incidence than P. vivax incidence, and mass drug administration (MDA) with an 8-aminoquinoline and a blood-stage partner drug was projected to cause the greatest reduction in P. vivax incidence, provided that adherence rates were high.Interpretation Control of the malaria outbreak in Southeastern Venezuela is feasible, should appropriate resources to support surveillance and control be brought to bear. Coupling the distribution of LLINs and a focal MDA with an 8-aminoquinoline and a blood-stage partner drug may lead to the greatest reduction in malaria incidence.Funding National Science Foundation; University of Notre Dame; National Institute of General Medical Sciences (grant number 1R35GM143029-01 to TAP);Evidence before the study We searched PubMed, bioRxiv, and medRxiv for articles in English published on or before May 25th, 2021 using the following keywords: “Venezuela”, “malaria”, AND “model*”. Previous studies have applied statistical models to characterize the relationship between malaria incidence and climate in Venezuela, concluding that the reproduction number is low and suggesting the feasibility of control. A study fitting a mechanistic transmission model to epidemiological data to allow for projecting the impact of alternative approaches to control has not been performed.Added value of the study We fitted Plasmodium falciparum and Plasmodium vivax transmission models to 20 years of weekly incidence data to estimate the transmission of both Plasmodium spp. and characterize the contribution of relapses and reinfections to P. vivax incidence in Bolívar, Venezuela. We also projected the likely impact of interventions in the region under alternative scenarios about control.Implications of the available evidence The burden of Plasmodium vivax relapses in Bolívar is underestimated from routine surveillance data, so control interventions must target the hypnozoite reservoir in the region. Mass drug administration (MDA) is projected to be impactful for both Plasmodium spp., though tradeoffs between coverage and adherence suggest that a focal MDA with an 8-aminoquinoline and a blood-stage partner drug may yield the greatest impact.Competing Interest StatementTAP is a statistical reviewer for The Lancet Infectious Diseases. All other authors have no competing interests to declare.Funding StatementJHH acknowledges support from a National Science Graduate Research Fellowship and a Richard and Peggy Notebaert Premier Fellowship. TAP acknowledges support from National Institute of General Medical Sciences (grant number 1R35GM143029-01).Author DeclarationsI confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.YesI confirm that all necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived, and that any patient/participant/sample identifiers included were not known to anyone (e.g., hospital staff, patients or participants themselves) outside the research group so cannot be used to identify individuals.YesI understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).YesI have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.YesDue to a data-sharing agreement, the underlying data can be publicly shared. All data requests should be made to LV (LVillegas{at}gdoassociates.com).